Laver Derek R, Attia John, Oldmeadow Christopher, Quail Anthony W
From the School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales, Australia (D.R.L., A.W.Q.) and the School of Medicine and Public Health, University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales, Australia (J.A., C.O., A.W.Q.).
Anesthesiology. 2017 Mar;126(3):495-506. doi: 10.1097/ALN.0000000000001519.
Halogenated anesthetics activate cardiac ryanodine receptor 2-mediated sarcoplasmic reticulum Ca release, leading to sarcoplasmic reticulum Ca depletion, reduced cardiac function, and providing cell protection against ischemia-reperfusion injury. Anesthetic activation of ryanodine receptor 2 is poorly defined, leaving aspects of the protective mechanism uncertain.
Ryanodine receptor 2 from the sheep heart was incorporated into artificial lipid bilayers, and their gating properties were measured in response to five halogenated anesthetics.
Each anesthetic rapidly and reversibly activated ryanodine receptor 2, but only from the cytoplasmic side. Relative activation levels were as follows: halothane (approximately 4-fold; n = 8), desflurane and enflurane (approximately 3-fold,n = 9), and isoflurane and sevoflurane (approximately 1.5-fold, n = 7, 10). Half-activating concentrations (Ka) were in the range 1.3 to 2.1 mM (1.4 to 2.6 minimum alveolar concentration [MAC]) with the exception of isoflurane (5.3 mM, 6.6 minimum alveolar concentration). Dantrolene (10 μM with 100 nM calmodulin) inhibited ryanodine receptor 2 by 40% but did not alter the Ka for halothane activation. Halothane potentiated luminal and cytoplasmic Ca activation of ryanodine receptor 2 but had no effect on Mg inhibition. Halothane activated ryanodine receptor 2 in the absence and presence (2 mM) of adenosine triphosphate (ATP). Adenosine, a competitive antagonist to ATP activation of ryanodine receptor 2, did not antagonize halothane activation in the absence of ATP.
At clinical concentrations (1 MAC), halothane desflurane and enflurane activated ryanodine receptor 2, whereas isoflurane and sevoflurane were ineffective. Dantrolene inhibition of ryanodine receptor 2 substantially negated the activating effects of anesthetics. Halothane acted independently of the adenine nucleotide-binding site on ryanodine receptor 2. The previously observed adenosine antagonism of halothane activation of sarcoplasmic reticulum Ca release was due to competition between adenosine and ATP, rather than between halothane and ATP.
卤代麻醉剂可激活心肌兰尼碱受体2介导的肌浆网钙释放,导致肌浆网钙耗竭,心脏功能降低,并为细胞提供抗缺血再灌注损伤的保护作用。卤代麻醉剂对兰尼碱受体2的激活作用尚不明确,保护机制的某些方面仍不确定。
将绵羊心脏的兰尼碱受体2整合到人工脂质双分子层中,并测量其对五种卤代麻醉剂的门控特性。
每种麻醉剂均可快速、可逆地激活兰尼碱受体2,但仅从细胞质一侧激活。相对激活水平如下:氟烷(约4倍;n = 8)、地氟烷和恩氟烷(约3倍,n = 9)、异氟烷和七氟烷(约1.5倍,n = 7,10)。半数激活浓度(Ka)在1.3至2.1 mM范围内(1.4至2.6最低肺泡浓度[MAC]),异氟烷除外(5.3 mM,6.6最低肺泡浓度)。丹曲林(10 μM与100 nM钙调蛋白)可使兰尼碱受体2抑制40%,但不改变氟烷激活的Ka值。氟烷增强了兰尼碱受体2的管腔和细胞质钙激活,但对镁抑制无影响。氟烷在有无三磷酸腺苷(ATP)(2 mM)的情况下均可激活兰尼碱受体2。腺苷是兰尼碱受体2的ATP激活的竞争性拮抗剂,在无ATP时不拮抗氟烷激活。
在临床浓度(1 MAC)下,氟烷、地氟烷和恩氟烷可激活兰尼碱受体2,而异氟烷和七氟烷无效。丹曲林对兰尼碱受体2的抑制作用基本消除了麻醉剂的激活作用。氟烷的作用独立于兰尼碱受体2上的腺嘌呤核苷酸结合位点。先前观察到的腺苷对氟烷激活肌浆网钙释放的拮抗作用是由于腺苷与ATP之间的竞争,而非氟烷与ATP之间的竞争。